Genzyme, a Sanofi company, has established a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of Leber congenital amaurosis type 1 (LCA-1), rare genetic disease that causes childhood blindness. Genzyme is providing $900,000 over three years to Dr. Shannon Boye, assistant professor of ophthalmology at the U of Florida, to fund her LCA-1 research focused on the gene mutation called guanylate cyclase (GUCY2D).   The...